Efficacy and Safety of Different Aceclofenac Treatments for Chronic Lower Back Pain: Prospective, Randomized, Single Center, Open-Label Clinical Trials

Jae-Ho Yang¹, Kyung-Soo Suk¹, Byung-Ho Lee², Woo-Chul Jung¹, Young-Mi Kang¹, Ji-Hye Kim¹, Hak-Sun Kim¹, Hwan-Mo Lee¹, and Seong-Hwan Moon¹

¹Department of Orthopedic Surgery, Yonsei University College of Medicine, Seoul; ²Department of Orthopedic Surgery, Catholic-Kwandong University College of Medicine, International St. Mary’s Hospital, Incheon, Korea.

Purpose: Nonsteroidal anti-inflammatory drugs are a mainstay for medical treatment of chronic lower back pain (CLBP). Increased dose intervals for medication have been associated with increased patient adherence to prescriptions. The purpose of this clinical trial was to compare the efficacy and safety of a once daily dose of aceclofenac controlled release (CR) and a twice daily dose of aceclofenac for CLBP management.

Materials and Methods: A prospective, randomized, single center, open-label clinical trial was performed to compare the efficacy and safety of aceclofenac CR (200 mg once daily) to aceclofenac dose (100 mg twice daily). Fifty patients in each group were enrolled for the study. The primary end point was Visual Analogue Scale (VAS) change at baseline to that at 2 weeks after medication and safety profiles. Also, change in quality of life measured by EuroQol 5D (EQ-5D) and Oswestry Disability Index (ODI) functional score for the lumbar spine were also assessed.

Results: Within groups at pre- and post-treatment, there were significant VAS reductions for aceclofenac CR and aceclofenac (p=0.028). EQ-5D increased significantly in both groups (p=0.037). ODI scores decreased significantly in both groups (p=0.012). However, there were no significant differences between aceclofenac CR and aceclofenac at pre- and post-treatment. Patients with aceclofenac CR showed significant increases in heartburn and indigestion and adverse gastrointestinal effects, compared to aceclofenac.

Conclusion: In patients with CLBP, aceclofenac CR and aceclofenac demonstrated significant symptomatic pain relief, improvement in quality of life and functional scores. Aceclofenac CR slightly increased gastrointestinal adverse effects, such as heartburn and indigestion.

Key Words: Chronic lower back pain, NSAIDs, aceclofenac

INTRODUCTION

Chronic lower back pain (CLBP) is prevalent worldwide in all age groups, and is associated with significant morbidity and high health care costs.¹,² CLBP treatments are multimodal, including medication, injection, physical therapy, exercise, back school, and sometimes surgery.³ Since surgical intervention is a last resort for CLBP, therapeutic treatment is acute and also requires patient adherence. Single or cocktail medical treatments with or without narcotics are conservative, widely accepted treatment practices. Nonsteroidal anti-inflammatory drugs (NSAIDs) are more often prescribed than muscle relaxants, antidepressants, antiepileptics, or narcotics.⁴

NSAIDs have many side effects, including adverse gastrointestinal effects, cardiovascular risk, and patient adherence.⁵,⁶ Cyclooxygenase-2 (COX-2) inhibitors are associated with fewer NSAID-related side effects. First-line COX-2 inhibitors are rec-
ommended for elderly patients presenting with osteoarthritis and gastrointestinal risk factors. Conventional NSAIDs can be prescribed to relatively young patients (<60 years) with musculoskeletal pain, in whom cardiovascular and gastrointestinal risk is relatively lower than patients >60 years.

Aceclofenac is a NSAID phenylacetic acid derivative \{2-[(2, 6-dichlorophenyl)amino]-[ phenylacetoxy]acetic acid\} widely and safely prescribed for musculoskeletal pain associated with rheumatic, degenerative, and traumatic injury etiologies.\(^7\)\(^9\) Furthermore, aceclofenac is effective for managing acute to CLBP, and has a wide safety profile.\(^10\) Aceclofenac and diclofenac are classified as acetic acid NASIDs, and are not associated with adverse cardiovascular events. NSAIDs that have been associated with adverse cardiovascular events include ibuprofen, celecoxib, and rofecoxib.\(^11\)

Dose interval is a crucial factor to assuring adherence to medical therapy. Increased dose interval has been associated with increased patient adherence to NSAID and osteoporotic medication.\(^12\) Controlled release (CR) maintained therapeutic serum levels for longer periods of time, with less gastrointestinal insult and increased patient adherence.\(^13\)

Accordingly, the purpose of this clinical trial was to compare the efficacy and safety of a once daily dose of aceclofenac CR and a twice daily dose of aceclofenac for CLBP management.

**MATERIALS AND METHODS**

**Study design**

A prospective, randomized, single center, open-label clinical trial was performed from February 2011 to December 2012 at an out-patient orthopedic clinic. The clinical trial protocol was approved by the Institutional Review Board of Yonsei University College of Medicine, Seoul, Korea (CR NO. 4-2010-0433). All subjects voluntarily submitted informed consent after thorough trial protocol explanation. The trial protocol was developed to compare the efficacy and safety of a once daily dose of aceclofenac CR (200 mg once daily) to a conventional twice daily aceclofenac dose (100 mg twice daily) (Fig. 1). Change in Visual Analogue Scale (VAS) (range 0-100; higher scores indicate greater pain)\(^14\) from baseline to 2 weeks after each medication was assessed. Safety profiles, change in quality of life as measured by EuroQoL 5D (EQ-5D),\(^15\)\(^16\) and Oswestry Disability Index (ODI)\(^17\)\(^18\) functional score for lumbar spine were also assessed. Data were analyzed with an intention-to-treat design.

The sample size calculation was based on differences in VAS score between the groups as obtained from a previous study.\(^13\) We calculated that a minimum of 45 patients would be needed in each treatment arm (allowing 20% dropouts) to detect a difference of at least 0.6 between groups with a two-sided type I error of 0.05 and 80% power.

**Subject selection criteria**

**Inclusion criteria**

Subjects of both genders aged 20 to 75 years reporting CLBP for at least 3 months or more, with pain intensity as measured by the VAS >40 mm, were enrolled. CLBP pain parameters included lower back pain >3 months, VAS >40 mm, CLBP with or without leg pain, daily pain attacks, and persistent pain. Plain lumbar radiographs were used to make diagnoses. Detailed procedures and hazard/benefit were carefully explained to all subjects.

**Exclusion criteria**

Subjects were excluded if they presented with acute fracture, malignancy, neurologic deficit, severe leg pain mandating surgery (lumbar disc herniation and spinal stenosis), fibromyalgia, compensation case, recent injection procedure, spinal surgery, history of allergy to aceclofenac, narcotic abuse, and alcohol abuse.

**Outcome measures**

**Visual Analogue Scale**

VAS mean level of back pain was assessed (0–100 mm pain scale: 0–none and 100–unbearable).

**EQ-5D**

EQ-5D consisted of five dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension had three levels of severity: 1) no problems, 2) some problems, and 3) extreme problems. EQ-5D was calculated thusly: each level of all dimensions with 1 as perfect, and 0 as worst quality of life. Current general health status was also assessed using the EQ-5D VAS (0–100, 100=best health status).

**Oswestry Disability Index**

The ODI is a 10-item self-report questionnaire measuring “back-specific function” with six response levels. Each item was scored from 0 to 5, higher scores being worse, which were transformed into a 0 to 100 scale. The 10 items included pain intensity, personal care, lifting, walking, sitting, standing, sleeping, sex life, social life, and traveling.

| Table 1. Patient Demographic Data |
|----------------------------------|
|                                | Aceclofenac CR | Aceclofenac | p value |
| Number of patients (n)          | 50             | 50          |         |
| Gender (male:female)            | 12:38          | 12:38       | 1.000*  |
| Age (y)                         | 57.6±11.3      | 56.9±11.1   | 0.799†  |
| Height (cm)                     | 160.2±8.1      | 159.6±7.7   | 0.695†  |
| Weight (kg)                     | 62.3±8.7       | 61.6±8.7    | 0.978†  |
| Duration of back pain (months)  | 50.0±55.1      | 91.6±119.0  | 0.184*  |

CR, controlled release.

*Chi-square test, †Unpaired t-test.
**Gastrointestinal assessment**
A separate questionnaire was utilized to assess post-treatment gastrointestinal symptoms. The following six items were included: indigestion, heartburn, nausea, vomiting, abdominal pain, and diarrhea graded as 1, 2, or 3 (minimal to severe symptoms limiting daily activities).

**Statistical analysis**
Values of VAS and EQ-5D VAS are expressed as mean with standard deviation, and values of EQ-5D and ODI are expressed as median with an inter-quartile range (IQR). To compare pain reduction in VAS and change in EQ-5D VAS after treatment, paired t-test was utilized. Quality of life improvement as EQ-5D and ODI were analyzed by using non-parametric statistics, such as Mann-Whitney U test, to compare changes in EQ-5D and ODI pre-and post-treatment in each group and Wilcoxon’s rank sum test to compare changes in EQ-5D and ODI between aceclofenac CR and aceclofenac groups. To compare gastrointestinal symptoms and adverse effects between groups, Fisher’s exact test was used. Significance level was set as p<0.05.

**RESULTS**
Of 106 subjects screened with the criteria described above, 100

---

**Table 2. Change of Pain in VAS, EQ-5D, EQ-5D VAS, and ODI**

| 100-mm VAS score          | Aceclofenac CR (n=50) | In group | Aceclofenac (n=50) | In group | Between group |
|---------------------------|-----------------------|----------|-------------------|----------|---------------|
|                           | Mean±SD               |          | Mean±SD           |          |               |
| Pre treat                 | 58.2±14.0             | p=0.028* | 64.0±13.1         | p=0.075* |               |
| Post treat                | 35.7±17.1             |          | 45.5±20.8         | p=0.109* |               |
| Alteration                | 22.6±15.8             |          | 18.6±17.7         | p=0.145* |               |

**EQ-5D VAS**

|                        | Aceclofenac CR (n=20) | In group | Aceclofenac (n=20) | In group | Between group |
|------------------------|-----------------------|----------|-------------------|----------|---------------|
| Pre treat              | 60.0±15.1             | p=0.071* | 62.7±14.1         | p=0.245* |               |
| Post treat             | 65.0±22.5             |          | 68.5±13           | p=0.125* |               |
| Alteration             | 5.0±14.7              |          | 5.8±16.7          | p=0.249* |               |

**EQ-5D**

|                      | Aceclofenac CR (n=50) | In group | Aceclofenac (n=50) | In group | Between group |
|----------------------|-----------------------|----------|-------------------|----------|---------------|
| Pre treat            | 0.5 (0.3–0.7)         | p=0.037† | 0.5 (0.3–0.7)     | p=0.423† |               |
| Post treat           | 0.7 (0.5–0.9)         |          | 0.6 (0.4–0.8)     | p=0.359† |               |
| Alteration           | 0.2 (-0.1–0.4)        |          | 0.1 (-0.1–0.3)    | p=0.438† |               |

**ODI**

|                      | Aceclofenac CR (n=50) | In group | Aceclofenac (n=50) | In group | Between group |
|----------------------|-----------------------|----------|-------------------|----------|---------------|
| Pre treat            | 34.6 (21.8–47.4)      | p=0.012† | 37.1±13.3 (23.8–50.4) | p=0.097† |               |
| Post treat           | 23.8 (11.3–36.5)      |          | 27.3±12.7 (14.6–40.0) | p=0.165† |               |
| Alteration           | 10.6 (-1.0–22.2)      |          | 10.4±12.9 (2.5–23.3) | p=0.581† |               |

CR, controlled release; VAS, Visual Analogue Scale; EQ-5D, EuroQoL 5D; EQ-5D VAS, EuroQol 5D Visual Analogue Scale; ODI, Oswestry Disability Index.

Values of VAS and EQ-5D VAS are expressed as mean with standard deviation (SD). Values of EQ-5D and ODI are expressed as median with an inter-quartile range (IQR) in parenthesis. *p<0.05: statistically significant.

**Table 3. Gastrointestinal Symptom Assessment**

| Gastrointestinal symptom | Aceclofenac CR (n=47) | Aceclofenac (n=50) | p value |
|--------------------------|-----------------------|-------------------|---------|
| Indigestion, n (%)       | 4 (8.5)               | 1 (2.0)           | 0.195   |
| Heartburn, n (%)         | 10 (21.3)             | 3 (6.0)           | 0.037   |
| Nausea, n (%)            | 2 (4.3)               | 1 (2.0)           | 0.610   |
| Vomit, n (%)             | 1 (2.1)               | 0 (0.0)           | 0.485   |
| Abdominal pain, n (%)    | 2 (4.3)               | 0 (0.0)           | 0.232   |
| Diarrhea, n (%)          | 1 (2.1)               | 0 (0.0)           | 0.485   |

CR, controlled release.

---

A separate questionnaire was utilized to assess post-treatment gastrointestinal symptoms. The following six items were included: indigestion, heartburn, nausea, vomiting, abdominal pain, and diarrhea graded as 1, 2, or 3 (minimal to severe symptoms limiting daily activities).
subjects were assigned to either aceclofenac CR (200 mg once daily) or conventional aceclofenac (100 mg twice daily) groups. There were 50 subjects in each group. During the study, only three subjects from the aceclofenac CR group dropped out of the study; all 50 aceclofenac subjects completed the study.

Before treatment, there were no differences between groups in demographic characteristics, duration of lower back pain, VAS, EQ-5D, or ODI (Table 1 and 2).

Table 4. Adverse Events

| System organ class                               | Preferred term                          | Aceclofenac CR (n=50) | Aceclofenac (n=50) | p value |
|-------------------------------------------------|-----------------------------------------|-----------------------|-------------------|--------|
| Gastrointestinal disorders, n (%)               | Adverse events                          | 10 (21.2)             | 7 (14.0)          | 0.595  |
| Dyspepsia                                       | 10 (21.2)                               | 4 (8.0)               |                   |        |
| Nausea                                          | 2 (4.2)                                 | 1 (2.0)               |                   |        |
| Constipation                                    | 2 (4.2)                                 | 0 (0.0)               |                   |        |
| Abdominal pain                                  | 2 (4.2)                                 | 0 (0.0)               |                   |        |
| Abdominal distension                            | 0 (0.0)                                 | 2 (4.0)               |                   |        |
| Vomiting                                        | 1 (2.1)                                 | 0 (0.0)               |                   |        |
| Diarrhea                                        | 1 (2.1)                                 | 0 (0.0)               |                   |        |
| Skin and subcutaneous tissue disorders, n (%)   | 5 (10.6)                                | 5 (10.0)              |                   | >0.999 |
| Swelling face                                   | 3 (6.4)                                 | 3 (6.0)               |                   |        |
| Pruritus                                        | 1 (2.1)                                 | 1 (2.0)               |                   |        |
| Skin disorder                                   | 1 (2.1)                                 | 0 (0.0)               |                   |        |
| Acne                                            | 0 (0.0)                                 | 1 (2.0)               |                   |        |
| General disorders and administration site conditions, n (%) | 9 (19.2)                                | 1 (2.0)               |                   | 0.016  |
| Generalized edema                               | 5 (10.6)                                | 0 (0.0)               |                   |        |
| Swelling                                        | 1 (2.1)                                 | 1 (2.0)               |                   |        |
| Edema peripheral                                | 1 (2.1)                                 | 0 (0.0)               |                   |        |
| Edema                                           | 1 (2.1)                                 | 0 (0.0)               |                   |        |
| Face edema                                      | 1 (2.1)                                 | 0 (0.0)               |                   |        |
| Nervous system disorders, n (%)                 | 3 (6.4)                                 | 4 (8.0)               |                   | >0.999 |
| Somnolence                                      | 2 (4.3)                                 | 1 (2.0)               |                   |        |
| Paresthesia                                     | 0 (0.0)                                 | 2 (4.0)               |                   |        |
| Dizziness                                       | 0 (0.0)                                 | 1 (2.0)               |                   |        |
| Headache                                        | 1 (2.1)                                 | 0 (0.0)               |                   |        |
| Investigations, n (%)                           | 0 (0.0)                                 | 4 (8.0)               |                   | 0.117  |
| Aspartate aminotransferase increased            | 0 (0.0)                                 | 2 (4.0)               |                   |        |
| Gamma-glutamyltransferase increased             | 0 (0.0)                                 | 2 (4.0)               |                   |        |
| Alanine aminotransferase increased              | 0 (0.0)                                 | 1 (2.0)               |                   |        |
| Infections and infestations, n (%)              | 1 (2.1)                                 | 1 (2.0)               |                   | >0.999 |
| Nasopharyngitis                                 | 0 (0.0)                                 | 1 (2.0)               |                   |        |
| Oral herpes                                     | 1 (2.1)                                 | 0 (0.0)               |                   |        |
| Musculoskeletal and connective tissue disorders, n (%) | 2 (4.3)                                | 0 (0.0)               |                   | 0.495  |
| Pain in extremity                               | 1 (2.1)                                 | 0 (0.0)               |                   |        |
| Musculoskeletal pain                            | 1 (2.1)                                 | 0 (0.0)               |                   |        |
| Vascular disorders, n (%)                       | 1 (2.1)                                 | 0 (0.0)               |                   | >0.999 |
| Flushing                                        | 1 (2.1)                                 | 0 (0.0)               |                   |        |
| Renal and urinary disorders, n (%)              | 1 (2.1)                                 | 0 (0.0)               |                   | >0.999 |
| Pollakiuria                                      | 1 (2.1)                                 | 0 (0.0)               |                   |        |
| Eye disorders, n (%)                            | 0 (0.0)                                 | 1 (2.0)               |                   | >0.999 |
| Abnormal sensation in eye                       | 0 (0.0)                                 | 1 (2.0)               |                   |        |
| Cardiac disorders, n (%)                        | 1 (2.1)                                 | 0 (0.0)               |                   | >0.999 |
| Palpitations                                    | 1 (2.1)                                 | 0 (0.0)               |                   |        |

CR, controlled release.
VAS (0–100 mm) pain intensity was significantly reduced in both groups: aceclofenac CR, before 58.2±14.0, after 35.7±17.1, p<0.05; aceclofenac, before 64.0±13.1, after 45.5±20.8, p<0.05. There was no significant difference in pain intensity between groups pre- and post-treatment (Table 2, Fig. 2A).

Quality of life as measured by calculated EQ-5D increased significantly in aceclofenac CR [before 0.5 (0.3–0.7), after 0.7 (0.5–0.9), p<0.05] and aceclofenac groups [before 0.5 (0.3–0.7), after 0.6 (0.4–0.8), p<0.05]. By contrast, there were no significant differences in EQ-5D general health status between aceclofenac CR and aceclofenac groups pre- and post-treatment. All EQ-5D dimensions (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression), except self-care in the aceclofenac group, showed level increases (Table 2, Figs. 2B and 3).

ODI spinal functional score decreased significantly in both aceclofenac CR [before 34.6 (21.8–47.4), after 23.8 (11.1–36.5), p<0.05] and aceclofenac groups [before 37.1±13.3 (23.8–50.4), after 27.3±12.7 (14.6–40.0), p<0.05]. In contrast, there was no significant difference between groups for other ODI items pre- to post-treatment (Table 2, Fig. 2C).

Gastrointestinal assessment revealed the aceclofenac CR group presented with more complaints than the aceclofenac group for all items: indigestion (4 vs. 1), heartburn (10 vs. 3) (p<0.05), nausea (2 vs. 1), vomiting (1 vs. 0), abdominal pain (2 vs. 0), and diarrhea (1 vs. 0). Among items of gastrointestinal assessment, only heartburn showed significant increase in aceclofenac CR group (p<0.05). However, the aceclofenac CR group presented only five complaints at the most severe symptom level, while the remaining 15 were at minimal and tolerable levels (Table 3).

Adverse effects post aceclofenac CR and aceclofenac treatment are presented in Table 4. In multiple categories (gastrointestinal, skin and subcutaneous, general physical, nervous system, serologic, infectious, musculoskeletal, vascular, renal, ocular, and cardiac) there were no significant differences in adverse effects between groups, except edema and swelling in general disorders and administration site conditions (p<0.05).

**DISCUSSION**

Both aceclofenac CR and aceclofenac were associated with significant pain reduction, increase in quality of life, improvement in spinal function, and tolerable minor adverse effects. For all measures only EQ-5D VAS showed no significant change pre- to post-treatment.

There was significant VAS reduction for aceclofenac CR (22.6) and aceclofenac (18.6), which was significant within groups pre- and post-treatment; however, there was no significant difference between groups pre- and post-treatment. Furthermore, increase in quality of life as calculated by EQ-5D was also significant within both groups. Alpha was set at 0.05, but p=0.10 for EQ-5D increase for both groups. Also, both groups showed significant improvement in ODI spinal functional score. There was no significant difference between groups in all ODI categories. A questionnaire specifically assessing gastrointestinal symptoms showed increased overall gastrointestinal complaints in both groups: aceclofenac CR (19 complaints) and aceclofenac (5 complaints). However, rate of heartburn was statistically significantly higher in the aceclofenac CR group. This protocol did not provide any gastrointestinal medications to protect stomach and duodenum mucosa, hence a single daily dose of aceclofenac CR (200 mg) might result in greater acidic insult to gastric mucosa than the lower twice daily dose (100 mg). There were no serious gastrointestinal effects seen in either group during the study interval. Among gastrointestinal complaints (20 incidences) on a questionnaire specialized for gastrointestinal symptoms in the aceclofenac CR group, only five complaints were severe in intensity, while the
remaining 15 complaints were minial intensity. Even though patients were enrolled in randomized fashion, duration of CLBP is different between aceclofenac CR and aceclofenac. Since CLBP is defined as lower back pain for more than 3 months, several outliers, such as CLBP more than years, seem to provide differences between groups. However, the duration of CLBP between group was statistically insignificant and chronicity of lower back pain seemed to have little effect on aceclofenac intervention, as shown in the results of uniform improvement in pain scale and quality of life measurements.

In conclusion, this prospective, randomized, single center, open-level aceclofenac CR and aceclofenac clinical trial in subjects with CLBP showed both dose regimens resulted in effective symptomatic pain relief, improvement in quality of life and functional scores, and tolerable adverse gastrointestinal effects.

REFERENCES

1. Witt CM, Pach D, Reinhold T, Wruck K, Brinkhaus B, Mank S, et al. Treatment of the adverse effects from acupuncture and their economic impact: a prospective study in 73,406 patients with low back or neck pain. Eur J Pain 2011;15:193-7.
2. Andrade NS, Flynn JP, Bartanusz V. Twenty-year perspective of randomized controlled trials for surgery of chronic nonspecific low back pain: citation bias and tangential knowledge. Spine J 2013;13:1698-704.
3. Chaparro LE, Furlan AD, Deshpande A, Mailis-Gagnon A, Atlas S, Turk DC. Opioids compared with placebo or other treatments for chronic low back pain: an update of the Cochrane Review. Spine 2014;39:556-63.
4. Cawston H, Davie A, Paget MA, Skljarevski V, Happich M. Efficacy of duloxetine versus alternative oral therapies: an indirect comparison of randomised clinical trials in chronic low back pain. Eur
5. Schattenkirchner M, Milachowski KA. A double-blind, multicentre, randomised clinical trial comparing the efficacy and tolerability of aceclofenac with diclofenac resin in patients with acute low back pain. Clin Rheumatol 2003;22:127-35.

6. Li J, Mansmann UR. Modeling of non-steroidal anti-inflammatory drug effect within signaling pathways and miRNA-regulation pathways. PLoS One 2013;8:e72477.

7. Li J, Mansmann UR. Non-steroidal anti-inflammatory drugs (NSAIDs). BMJ 2013;346:f3195.

8. Bae SK, Kim SH, Lee HW, Seung SJ, Shin SY, Lee SH, et al. Pharmacokinetics of a new once-daily controlled-release formulation of aceclofenac in Korean healthy subjects compared with immediate-release aceclofenac and the effect of food: a randomized, open-label, three-period, crossover, single-centre study. Clin Drug Investig 2012;32:111-9.

9. Legrand E. Aceclofenac in the management of inflammatory pain. Expert Opin Pharmacother 2004;5:1347-57.

10. Pareek A, Chandurkar N, Chandanwale AS, Ambade R, Gupta A, Bartakke G. Aceclofenac-tizanidine in the treatment of acute low back pain: a double-blind, double-dummy, randomized, multicentric, comparative study against aceclofenac alone. Eur Spine J 2009; 18:1836-42.

11. Trelle S, Reichenbach S, Wandel S, Hildebrand P, Tschannen B, Villiger PM, et al. Cardiovascular safety of non-steroidal anti-inflammatory drugs: network meta-analysis. BMJ 2011;342:c7086.

12. Vestergaard P, Hermann P, Jensen JE, Eiken P, Mosekilde L. Effects of paracetamol, non-steroidal anti-inflammatory drugs, acetylsalicylic acid, and opioids on bone mineral density and risk of fracture: results of the Danish Osteoporosis Prevention Study (DOPS). Osteoporos Int 2012;23:1255-65.

13. Pareek A, Chandurkar N, Gupta A, Sirsikar A, Dalal B, Jesalpura B, et al. Efficacy and safety of aceclofenac-cr and aceclofenac in the treatment of knee osteoarthritis: a 6-week, comparative, randomized, multicentric, double-blind study. J Pain 2011;12:546-53.

14. Ogon M, Krismer M, Stöllner W, Kantner-Rumplmair W, Lampe A. Chronic low back pain measurement with Visual Analogue Scales in different settings. Pain 1996;64:425-8.

15. Johnsen LG, Hellum C, Nygaard OP, Storheim K, Brox JI, Rossvoll, et al. Comparison of the SF6D, the EQ5D, and the Oswestry Disability Index in patients with chronic low back pain and degenerative disc disease. BMC Musculoskelet Disord 2013;14:148.

16. Whynes DK, McCahon RA, Ravenscroft A, Hodgkinson V, Evley R, Hardman JG. Responsiveness of the EQ-5D health-related quality-of-life instrument in assessing low back pain. Value Health 2013; 16:124-32.

17. Fairbank JC, Couper J, Davies JB, O’Brien JP. The Oswestry low back pain disability questionnaire. Physiotherapy 1980;66:271-3.

18. Fairbank JC, Pyseent PB. The Oswestry Disability Index. Spine (Phila Pa 1976) 2000;25:2940-52.